AT-301 (Medigen Biotechnology)

AT-301 is an inactivated H5N1 influenza virion vaccine developed by Medigen Biotechnology. Produced using Madin-Darby Canine Kidney (MDCK) cell culture technology rather than traditional egg-based methods, it is designed to provide active immunization against the H5N1 subtype of the influenza A virus (avian influenza). The vaccine functions by inducing a humoral immune response, specifically stimulating the production of neutralizing antibodies directed against the viral hemagglutinin (HA) protein. Clinical evaluation has focused on a Phase 1 prospective study investigating the safety, reactogenicity, and immunogenicity of the vaccine across various dosage levels (7.5 µg, 15 µg, and 30 µg HA) in healthy adult subjects.

Other names

Inactivated H5N1 Influenza Virion VaccineMedigen H5N1 VaccineH5N1 influenza vaccineH-5N1 influenza vaccineH 5N1 influenza vaccine